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We conducted a double blind, randomised, placebo-controlled, crossover study evaluating
the effects of halving inhaled steroid dosage plus salmeterol, or salmeterol and
tiotropium. Eighteen life-long non-smoking severe asthmatics [mean FEV1 1.49 l (51%)]
were run-in for 4 weeks on HFA-fluticasone propionate 1000 mg daily, and were
subsequently randomised to 4 weeks of either (a) HFA-fluticasone propionate 500 mg BD/
salmeterol 100 mg BD/HFA-tiotropium bromide18 mg od; or (b) fluticasone propionate
500 mg BD/salmeterol 100 mg BD matched placebo. Measurements of spirometry and body
plethysmography were made. Adding salmeterol to half the dose of fluticasone led to a
mean improvement (95% CI) vs. baseline in morning PEF of 41.5 (14.0–69.0) l/min
[po0.05]; and RAW of 0.98 (0.14–1.8) cm H2O/l/s [po0.05]. Adding salmeterol/tiotropium
produced similar improvements in PEF and RAW, but also improved FEV1 by 0.17
(0.01–0.32) l [po0.05]; FVC 0.24 (0.05–0.43) l [po0.05] and reduced exhaled NO by 2.86
(0.12–5.6) ppb [po0.05]. RV and TLC were not altered by either treatment; there were no
significant changes in symptoms or quality of life compared with baseline. Addition of
salmeterol/tiotropium to half the dose of fluticasone afforded small, but significant
improvements in pulmonary function. These effects were not associated with commensu-
rate changes in subjective symptoms or quality of life.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
632983; fax: +441382644972.
ee.ac.uk (B.J. Lipworth).Introduction
Asthma is an inflammatory disorder of the airways and the
spectrum of disease is wide, ranging from intermittent mild
disease, to severe disease.1,2 These severe, difficult to
manage patients present with poorly controlled asthma;
often despite high doses of inhaled corticosteroids. True
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To evaluate the dose of fluticasone in combination with salmeterol and tiotropium 1219steroid resistant asthma is rare, with an incidence of 1 in
1000 to 1 in 10,000 asthmatic patients,3,4 however a cohort
of severe asthmatics do demonstrate minimal therapeutic
benefit from the highest doses of inhaled and oral,
corticosteroids. The mechanisms of this relative steroid
resistance are not fully understood, however it may be due
to the severity of the disease itself (via inactivation of
glucocorticoid receptors by IL-1a and TNF-d5,6), or by high
doses of b2 agonists (due to inactivation of glucocorticoid
receptors by b2 agonist activated cyclic adenosine monopho-
sphate response binding element7,8).
Progressive airflow obstruction occurs in severe asthmatic
patients,9,10 the exact mechanism of this deterioration is
not known, however it may be due to airway remodelling
secondary to uncontrolled chronic airway inflammation.11
The fibrotic changes seen in remodelled airways are
unresponsive to ICS therapy, and as such ever-increasing
high doses of steroid at this stage can be ineffective. The
systemic burden of inhaled corticosteroid should not be
underestimated, with even clinically moderate doses of
modern ICS leading to significant hypothalamic–pituitary–
adrenal axis suppression,12 and bone demineralization.13
The latest asthma guidelines suggest ‘‘Stepping-down’’
the dose of prescribed ICS to the minimum dose that
gives adequate control. In the severe patient group, this
is a difficult clinical problem, as many patients will not
achieve ‘‘adequate control’’ without, or despite a high
dose of ICS. The use of second line therapies has
been proposed as a method to not only improve asthma
control, but also give a steroid sparing effect, allowing step
down of ICS.
Treatment options for severe asthma with airway remo-
delling are, therefore, limited, and, in reality, most patients
are prescribed a combination of ICS and various bronchodi-
lators such as b2 agonists, anticholinergics and theophyl-
lines. The use of second line agents may facilitate step down
of inhaled corticosteroid dosage, without deterioration in
pulmonary function of quality of life.
To our knowledge, there have been no studies that
investigate the potential benefit of the addition of
long acting bronchodilators to facilitate step down
of ICS in the severe cohort of patients. The present study
aims to demonstrate that inhaled corticosteroids may
be stepped down safely with adjuvant therapy of long
acting b2 agonists with or without tiotropium; we measure
the benefits in terms of effort dependent pulmonary
function testing, body plethysmography and quality of life
scoring.Methods
Patients
Twenty-six patients were initially enrolled into the rando-
mised, placebo-controlled, crossover study. We identified
patients from our database of volunteers, who were life-
long non-smokers with severe persistent asthma, evidence
of airway remodelling; that is, severe volume-dependent
airway closure on an expiratory flow volume loop and a
reduced FVC% predicted.Screening visit
Patients attended an initial visit to assess eligibility and
perform measurements. All routine first and second line
treatment was stopped. Patients were then prescribed HFA-
fluticasone 1000 mg pMDI (as 2 puffs bd of Flixotide 250 mg
per actuation, Flixotide Evohaler, GlaxoSmithKline, Ux-
bridge, UK) for a run-in period of 4 weeks.
Study visits
They returned for visit one (baseline) for spirometry
measurements and reversibility testing. Reversibility was
assessed on 2 separate days in random order with either
salbutamol 400 mg, as 2 puffs of Ventolin Accuhaler 200 mg
per actuation (GlaxoSmithKline, Uxbridge, UK), followed by
ipratropium bromide 80 mg, as 2 puffs of Atrovent Aerocaps
40 mg per actuation (Boerhinger Ingelheim, Bracknell, UK) or
the reverse order. FEV1 and FVC were recorded 30min after
the administration of salbutamol or ipratropium. The second
drug in sequence was given 30min after the first drug.
Following run-in, the dose of HFA-fluticasone was halved
to 500 mg daily. To facilitate step down patients received
either fluticasone and salmeterol, as Seretide Evohaler
125/25 mg per actuation, 2 puffs BD (GlaxoSmithKline,
Uxbridge, UK), and tiotropium, CFC formulation 9mg per
actuation, two puffs OD, 18 mg OD (Cipla Ltd, Mumbai, India)
or fluticasone, salmeterol and matched placebo.
Patients were randomised to the study tiotropium or
placebo groups in a crossover fashion, with measurements
made after 4 weeks of each treatment (Fig. 1).
Comparisons were made with reference to the baseline
values after fluticasone propionate 1000 mg daily, in order to
evaluate the effects of halving the fluticasone dose with the
addition of either salmeterol alone or salmeterol and
tiotropium.
Inclusion criteria
Inclusion criteria were; forced expiratory volume in 1 s
(FEV1)p65% predicted, FVCo80% predicted, FEF25–75o50%
predicted at visit one, males or females over 18 years of
age, a positive reversibility (at least 15% improvement) to
ipratropium bromide and salbutamol, and no evidence of
an upper respiratory tract infection or the use of oral
corticosteroids in the 3 months preceding screening day.
All patients gave informed written consent, and the study
was approved by the Tayside Committee for Medical
Research Ethics.
Laboratory testing
At each visit blood was taken for estimation of eosinophil
catatonic protein (ECP) using a UniCAP100 (Pharmacia, UK).
Body plethysmography
Body plethysmography was performed using an Autolink
Whole Body Plethysmograph (PK Morgan, Kent, UK). Two
repeatable tests performed were airway resistance and
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Figure 1 Flow chart of the study design. FP—fluticasone propionate, doses in mg: SM—salmeterol; TIO—tiotropium; PL—placebo;
V—visit.
T. Fardon et al.1220SVG/TLC using the panting method with cheek support and
tidal breathing. Patients were trained in the technique prior
to measurements.
Exhaled NO
Patients underwent exhaled nitric oxide (NO) measurement
using an integrated LR2000 clinical real-time NO gas analyser
under standardised conditions.14 The normal cut off value for
patients in our laboratory is o6 parts per billion.
Pulmonary function
Spirometry was performed according to American Thoracic
Society criteria15 using a Micro Medical SuperSpiro (Micro
Medical Ltd, Rochester, UK). FEV1 was measured in
triplicate, the highest being used.
Mini juniper quality of life questionnaires
(Mini-AQLQ)
At each visit a Mini AQLQ16 was given out to be self-
administered by the patient to assess their quality of life
scores during the study.
Domiciliary diaries
Domiciliary PEF was measured twice daily throughout the
study using a Mini-Wright peak flow meter (Clement Clarke,
Essex, UK); the best of 3 measurements was recorded.
Diurnal reliever use and symptom scores on a 0–3 scale,
ranging from 0 meaning no symptoms to 3 meaning severe
symptoms, were recorded.
Statistical analysis
A total 16 completed patients were required to achieve 80%
power to detect a 15% difference in FEV1 between
treatments in this cross-over studyAbsolute values were compared by multifactorial analysis
of variance over all three treatments: (a) fluticasone
1000 mg daily alone (FP1000); (b) fluticasone 500 mg/salme-
terol 100 mg daily/placebo (FP/SM/PL); and (c) fluticasone
500 mg daily/salmeterol 100 mg daily/tiotropium18 mg OD
(FP/SM/TIO).
Where an overall significant difference was found, pair-
wise comparisons were carried out, with Bonferroni correc-
tion for multiple range testing. Thus, pair-wise comparisons
are quoted as being either significant (po0.05, two tailed)
or not. Statistical analysis was performed using SPSS&
version 11.0 (SPSS Inc., Chicago, IL, USA).
Results
Twenty-six patients were initially enrolled into the study of
which 18 (11 males) completed (mean age 54, SEM 2.44).
Demographic data for all patients are given in Table 1.
Pulmonary function results following all treatments are
shown in Fig. 2 and Table 2. Adequate treatment periods
prior to assessment lead to no carry over effects for any
outcome measure.
Screening visit and baseline
The conversion of patients from their regular ICS dosing
(mean 782 mg/day, SEM 96) to fluticasone propionate 1000 mg
daily did not significantly improve any outcome measure.
Reversibility
Acute responses (Fig. 3)
The sequence of salbutamol then ipratropium gave 8.6
(0.45–16.76)% (po0.05) more improvement in FEV1 than the
opposite sequence.
The FEV1 response to salbutamol alone [i.e., given first in
sequence] was 22.6 (4.1) as % change, while the FEV1
response to ipratropium alone [i.e., given first in sequence]
was 17.6 (3.7) as % change, with no significant difference
between sequences. Corresponding data for FVC showed a
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Table 1 Demographics.
Subject M/F Age FEV1
(%)
FVC
(%)
FEF2575
(%)
VC
(%)
FRC
(%)
RV
(%)
TLC
(%)
RV/TLC RV/TLC
(%)
RAW
(%)
ICS BDP
equiv
Others
1 M 51 41 63 0.76 66 152 189 123 50 240 235 BDP 800 TH,S
4 M 45 45 56 1.08 78 111 143 96 44 157 165 FP 1000 SM, S
5 M 51 52 66 0.99 183 241 138 56 186 75 BDP 500 FF, S
7 M 68 65 82 1.14 99 237 272 163 66 188 78 BDP 800 FF, Z, S
8 M 56 60 70 1.36 63 136 206 122 57 183 253 None S
9 M 67 51 54 1.15 78 253 262 165 58 165 257 FP/SM 1000 S
10 F 64 29 48 0.31 61 291 264 181 61 148 143 BUD/FM 400 T, IP
11 F 65 32 31 0.54 34 217 264 142 80 195 313 BDP 800 TH, B, SN, S
12 F 47 50 73 0.72 76 182 192 136 49 148 196 FP/SM 1000 OP
13 M 53 61 54 1.27 74 142 203 128 54 180 146 BDP 400 S
15 F 64 49 89 0.29 94 166 169 121 58 141 119 BDP 400 S
16 F 39 60 78 0.98 78 251 345 161 68 219 178 BDP 1600 S
18 F 53 63 67 1.09 60 259 330 173 72 200 97 BUD 800 T
19 M 35 53 65 1.45 64 200 228 118 48 192 171 BDP 400 SM, S
20 M 37 56 73 1.52 69 133 133 95 35 140 171 BDP 800 SM, S
23 F 64 51 54 0.93 40 207 240 138 72 175 193 FP/SM 200 S
24 M 52 41 66 0.67 77 244 374 176 68 226 137 BDP 1600 TH, S
25 M 54 59 78 1.27 92 188 216 138 51 164 84 BUD/FM 800 OP,TH
Mean 54 51.0 64.8 0.97 67.6 199 249 140 58.8 186 160
SEM 2.44 2.41 3.26 0.09 3.49 10.8 16 5.39 2.37 9.32 15.2
*TH—theophylline, S—salbutamol, SM—salmeterol, FF—formoterol fumarate, Z—zafirlukast, T—terbutaline, IP—ipratropium
bromide, B—bambuterol, SN—salbutamol nebuliser, OP—oxitropium bromide.
Figure 2 Pulmonary function results as FEV1% predicted for all treatments. FP 1000—fluticasone 1000 mg daily; FP 500/SM/
PL—fluticasone 500 mg daily, salmeterol 50 mg BD and placebo BD; FP 500/SM/TIO—fluticasone 500 mg daily, salmeterol 50mg BD and
tiotropium 18mg OD. *Denotes a difference of po0.05.
To evaluate the dose of fluticasone in combination with salmeterol and tiotropium 1221
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T. Fardon et al.1222significant difference (po0.05) between the first and
second drug irrespective of sequence.
The addition of salbutamol to ipratropium conferred a
7.47 (1.89–13.05)% (po0.05) improvement in FEV1. The
addition of ipratropium to salbutamol conferred a 7.24
(3.46–11.02)% (po0.05) improvement in FEV1Acute vs. chronic response
The acute response in FEV1 of a single dose of salbutamol
was compared to the chronic response to fluticasone
propionate 500 mg daily and salmeterol (Fig. 4). The mean
(95% CI) difference in acute vs. chronic response was 9
(1.5–16.6)% predicted (po0.05) in favour of the response to
salbutamol. The mean difference in FVC was 10.4
(1.66–19.1)% predicted (po0.05) in favour of the response
to salbutamol.
Similarly, the acute response in FEV1 to salbutamol and
ipratropium given to patients receiving fluticasone propio-
nate 1000 mg daily was compared with the chronic responseTable 2 Mean lung function values (SEM).
Treatment FP 1000 FP 500/SM/PL FP 500/SM/TIO
FEV1 (l) 1.62 (0.14) 1.73 (0.12) 1.79* (0.12)
FEV1 (%) 55 (2.9) 60 (3.1) 62*(2.9)
FVC (l) 2.44 (0.2) 2.57 (0.19) 2.68* (0.19)
FVC (%) 68 (3.6) 72 (3.1) 75* (2.8)
FEF2575 (l) 1.12 (0.1) 1.24 (0.1) 1.21 (0.09)
FEF2575 (%) 32 (2.5) 36 (2.5) 36 (2.4)
*Denotes a significant difference vs. FP1000 (po0.05).
FP—fluticasone propionate (doses in mg daily); SM—salme-
terol (50 mg BD); PL—placebo; TIO—tiotropium (18 mg OD).
Figure 3 Acute reversibility in FEV1, as % change from baseline
2nd—salbutamol 400 mg given first followed by Ipratropium 80 mg;
salbutamol 400 mg given 2nd. *Denotes a difference of po0.05.to fluticasone propionate 500 mg daily plus salmeterol and
tiotropium (Fig. 4). The mean (95% CI) difference in
response was 13.7 (0.6–28.0)% predicted (po0.05) in favour
of the response to salbutamol and ipratropium. The mean
difference in FVC was 11.4 (2.8–20.0)% predicted (po0.05)
in favour of the response to salbutamol and ipratropium.
Individual data are shown in Fig. 5.
Chronic dosing effects on spirometry and peak flow
In comparison with baseline measurements after fluticasone
1000 mg daily, halving the dose of fluticasone to 500 mg daily
in conjunction with salmeterol 100 mg daily and placebo or
fluticasone 500 mg daily plus salmeterol 100 mg daily plus
tiotropium 18 mg daily, resulted in significant improvements
in morning and evening domiciliary peak expiratory flow
(PEF) (Fig. 6). The mean (95% CI) improvement in morning
PEF was 41.5 (14.4–68.6) l/min (po0.01) and 55.3
(31.97–78.7) l/min (po0.01) (FP/SM/PL and FP/SM/TIO,
respectively). The mean (95% CI) improvement in evening
PEF was 37 (12–63) and 44 (26–62) l/min (po0.01) (FP/SM/
PL and FP/SM/TIO, respectively).
The triple combination of FP/SM/TIO resulted in mean
(95% CI) improvements FEV1 of 0.17 (0.03–0.31) l (po0.05),
6.8 (0.8–12.8)% predicted (po0.05); and FVC of 0.24
(0.06–0.42) l (po0.05), 7.4 (1.87–13.02)% predicted
(po0.05) compared with fluticasone 1000mg daily (Fig. 2).
There were no significant differences between the double
and triple therapy combinations for any outcome measures.
Effects on body plethysmography outcomes
Data for 17 patients were analysed, due to malfunction of
the body plethysmograph for patient 19 at visit 1. Bodyvalue after fluticasone propionate 1000 mg daily. Salb 1st/Iprat
Iprat 1st/Salb 2nd—ipratropium 80 mg given 1st followed by
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Figure 4 Acute vs. chronic dosing as % change in FEV1 from fluticasone propionate 1000 mg daily. FP 1000/Salb—fluticasone 1000 mg
daily plus 400 mg salbutamol; FP 500/SM/PL—fluticasone 500 mg daily, salmeterol 50mg BD and placebo BD; FP 1000/Salb/
Ipr—fluticasone 1000 g daily plus 400 mg salbutamol and 80mg ipratropium bromide; FP 500/SM/TIO—fluticasone 500 mg daily,
salmeterol 50mg BD and tiotropium 18 mg OD. *Denotes a difference of po0.05.
To evaluate the dose of fluticasone in combination with salmeterol and tiotropium 1223plethysmography results are shown in Table 3. There was a
significant reduction in RAW% predicted after FP/SM/PL:
32.87% (CI 2.4–63.4) (po0.05) and after FP/SM/TIO: 34%
(CI 6.7–61.3) (po0.05) when compared with FP 1000 daily.
There were no significant differences in RV or TLC for the
same comparisons.
Exhaled NO, ECP and Mini AQLQ
There was a significant reduction in exhaled NO values
following treatment with FP/SM/TIO compared with FP1000
of 2.86 ppb (CI 0.12–5.6) (po0.05). There was no significant
difference in ECP values, or in any of the domains for the
Mini-AQLQ with any treatment (Table 4).
Discussion
The present study shows that the concept of safe step
down of inhaled corticosteroids with the addition of long
acting bronchodilators can be supported in this severe
cohort of patients: the addition of salmeterol alone to
half the dose of fluticasone afforded small, but signi-
ficant improvements in PEF and RAW, however the
addition of salmeterol and tiotropium to half the dose of
fluticasone also afforded further significant improvements in
FEV1, FVC and eNO. These improvements were not asso-
ciated with commensurate improvements in quality-of-life
scores.
The initial run-in for the present study involved optimisa-
tion of anti-inflammatory treatment by the administration
of 1000mg daily of fluticasone propionate. At screening, themean dose of inhaled corticosteroid was 782 mg daily of CFC-
BDP equivalent, yet despite increasing this dose to an
equivalent daily dose of 2000 mg CFC-BDP (i.e., fluticasone
1000 mg daily) during the run in, there were no significant
improvements in any pulmonary function, body plethysmo-
graphy or quality-of-life measures when comparing values
pre- vs. post-fluticasone run in. It is likely, therefore, that
this group of patients did demonstrate a significant degree
of relative steroid resistance, particularly as they were
shown to have significant improvements in FEV1 and FVC
when maximally bronchodilated. Current guidelines advo-
cate that optimising steroid therapy is important in this
severe cohort of patients; however, our findings suggest that
there is little benefit in using a 1000 mg daily dose of
fluticasone propionate in severe asthmatics, but it is known
that there are significant effects on the hypothalamic–
pituitary–adrenal axis at this dose.12
It is clear that the use of long-acting bronchodilating
therapies gives symptomatic improvement at all severities
of asthma. Lemanske et a1.17 showed that adding salmeterol
during ICS step down improves lung function, but had
no effect on exacerbations in patients with moderate
to severe asthma, and Van Noord et al.18 showed that
adding salmeterol to fluticasone propionate was as effec-
tive as doubling the dose of fluticasone, in terms of
pulmonary function and exacerbations, in moderate to
severe asthmatic patients. However, Currie et al showed
that adding salmeterol to fluticasone propionate is
inferior to doubling the dose of fluticasone propionate, in
terms of inflammatory markers.19 In the present study,
PEF was improved by stepping down ICS dose with
salmeterol, and there was no deterioration in inflammatory
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Figure 5 Individual data for comparison of acute and chronic bronchodilator effects. FP1000/Salb—fluticasone 1000 mg daily and
salbutamol 400 mg; FP500/SM/PL—fluticasone 500 mg daily, salmeterol 50 mg BD and placebo BD. FP1000/Salb/Ipr—fluticasone
1000 mg daily, salbutamol 400 mg and ipratropium 80 mg; FP 500/SM/TIO—fluticasone 500 mg daily, salmeterol 50 mg BD and tiotropium
18mg OD.
T. Fardon et al.1224surrogates (ECP and eNO), indeed there was a non-
significant trend towards improvement in eNO in the
salmeterol alone arm.
The addition of long-acting b2-agonists to corticosteroid
treatment has been shown to improve measures of pulmon-
ary function.20–24 In these studies, the selected patients had
marked salbutamol reversibility, which is similar to thepresent study (22 % salbutamol reversibility). We, too, have
shown a 12% improvement in FEV1 after the addition of
salmeterol to fluticasone propionate 500 mg daily, compared
with the post run in baseline value of fluticasone propionate
1000 mg daily, however the patients’ % predicted FEV1 in the
present study was lower that other previous studies. Despite
this, the lack of concomitant improvement in quality-of-life
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Figure 6 Mean Peak Flow Rates following 4 weeks of treatment. FP 1000—fluticasone 1000 mg daily; FP 500/SM/PL—fluticasone
500 mg daily, salmeterol 50 mg BD and placebo BD; FP 500/SM/TIO—fluticasone 500 mg daily, salmeterol 50 mg BD and tiotropium 18mg
OD. *Denotes a difference of po0.05.
Table 3 Mean (SEM) body plethysmography values for airway resistance (RAW), residual volume (RV),and total lung capacity
(TLC).
Treatment FP 1000 FP500/SM/PL FP500/SM/TIO
RAW (cm) H2O (l/s) 3.88 (0.34) 2.96* (0.27) 2.97* (0.10)
RAW (%) 149.3 (12.2) 116.67* (12.5) 115.3* (15.9)
RV (L) 4.44 (0.31) 4.38 (0.41) 3.87 (0.23)
RV (%) 235.4 (16.1) 231.8 (21.8) 205.8 (13.2)
TLC (L) 7.46 (0.38) 7.84 (0.3) 7.2 (0.28)
TLC (%) 136.8 (5.5) 145.2 (6.2) 133.2 (5.2)
*Denotes a difference from FP1000 of po0.05. FP—fluticasone propionate (doses in mg daily); SM—salmeterol (50 mg BD); PL—placebo;
TIO—tiotropium (18 mg OD).
Table 4 Mean (SEM) quality-of-life scores for each domain and for overall score.
FP1000 FP500/SM/PL FP500/SM/TIO
Overall 5.0 (0.32) 5.3 (0.35) 5.3 (0.35)
Activity 5.4 (0.45) 5.6 (0.4) 5.6 (0.4)
Symptoms 5.0 (0.37) 5.4 (0.3) 5.4 (0.31)
Emotions 4.6 (0.36) 5.0 (0.49) 5.1 (0.44)
Environment 4.6 (0.36) 5.0 (0.4) 5.0 (0.4)
*Denotes a difference from FP1000 of po0.05. FP—fluticasone propionate (doses in mg daily); SM—salmeterol (50 mg BD); PL—placebo;
TIO—tiotropium (18 mg OD).
To evaluate the dose of fluticasone in combination with salmeterol and tiotropium 1225improvements in our patients, perhaps suggests that there is
little clinical benefit to be had from maximally bronchodi-
lating patients with severely impaired lung function,
although much larger studies would be required to confirm
our preliminary findings.Although there is speculation over the anti-inflammatory
effects of long acting beta agonists8,25,26 there is conflicting
data, showing that surrogates of inflammation are not
improved by the addition of salmeterol. There is, indeed,
evidence to show that halving the dose of fluticasone in
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T. Fardon et al.1226combination with salmeterol leads to a significant deteriora-
tion in inflammation, despite maximising pulmonary func-
tion.19 In the present study, there was a significant
difference between exhaled nitric oxide levels (eNO) in
the FP/SM/TIO limb of the study compared to baseline of
FP1000 mg daily, which is interesting considering the dose of
ICS was halved. It has been shown that the dose response of
eNO to inhaled corticosteroid reaches plateau at 800 mg CFC-
BDP equivalent (400 mg daily FP); which may explain the
effective suppression of eNO.27 There was also a non-
significant trend towards suppression of eNO in the FP/SM
limb of the study. Perhaps this is further evidence that the
bronchodilating drugs may have an anti-inflammatory action
in asthmatic patients. We analysed exhaled nitric oxide,
however recent evidence advocates the use of alveolar NO
as a better assessment of inflammatory status in asthma.28
The parasympathetic nervous system is dominant in control
of airway smooth muscle tone,29 and despite the abundance
of b2 adrenoceptors within the smooth muscle, no sympa-
thetic nervous system innervation of the airway smooth
muscle cells has been proven.30 As such there is a role for
anticholinergic drugs in the management of chronic airway
constriction. Anticholinergic therapy has been utilised in the
management of chronic obstructive pulmonary disease
(COPD) in the form of short- and long-acting moieties.
Recently developed long-acting anticholinergic tiotropium
bromide has been shown to confer positive effects of
pulmonary function and quality of life in patients with
COPD.31 Although there is little evidence, and no license, for
the use of tiotropium in asthma, there is a rationale for its
use in severe asthma. COPD and severe asthma with airway
remodelling have similar pathophysiological features, and
may have a common predisposition11—the use of additional
bronchodilation in severe asthma may give rise to similar
improvements in pulmonary function and quality of life. We
chose to evaluate tiotropium as add on to fluticasone and
salmeterol, rather than fluticasone alone, as current guide-
lines advocate the use of the ICS and LABA combination for
the sever cohort of patients. The rationale for use of
tiotropium was to produce additive effect, rather than to
replace the use of LABA in this group.
We did not show any effect of sequence on the response
to randomised treatments, in terms of whether Tiotropium
was given prior to or after placebo. This is to be expected
given that the half life of tiotropium is 24 h, with five half
lives being required to washout the drug, as compared to the
4 weeks period for each randomised treatment.
To assess the potential benefit of adding a long acting b2
agonist and anticholinergics to ICS we assessed the effect of
short acting variants. Treatment with salbutamol lead to an
improvement in FEV1 of 22 %, however further treatment
with ipratropium led to a further, significant increase in FEV1
and FVC. Thus, the ceiling for bronchodilation is not reached
by salbutamol alone, giving room for further therapeutic
benefit on an individual patient basis. Despite the significant
additive acute effect of ipratropium to salbutamol, this was
not reflected by any significant improvement in any outcome
measure when tiotropium was added to salmeterol during
chronic dosing, in patients receiving fluticasone propionate
500 mg daily. Moreover, the acute response to salbutamol
alone or salbutamol plus ipratropium in patients taking
fluticasone propionate 1000 mg daily was found to besignificantly greater than the chronic response to salmeterol
alone or salmeterol plus tiotropium in patients taking
fluticasone propionate 500 mg daily. This in turn suggests
that acute reversibility testing with short acting bronchodi-
lators may not predict the magnitude of chronic dosing
response to long acting bronchodilators. Salbutamol has a
relative intrinsic efficacy of 0.8 with respect to isoprenalline
at the b2 receptor, whereas salmeterol has a relative
intrinsic efficacy of 0.4, explaining why there may be larger
response to salbutamol over salmeterol. Tiotropium is a
selective anti-cholinergic treatment, more selective for M1
and M3 receptors than ipratropium, and dissociates more
rapidly from the M2 receptor, thus releasing the ‘‘Brake’’ on
adrenergic smooth muscle relaxation that can occur with
non-selective anti-cholinergic blockers.32 Thus, one might
expect that the tiotropium response would if anything be
greater than the ipratropium response. In this respect Van
Noord18 found tiotropium OD to be more effective than
ipratropium QDS, in terms of FEV1 in COPD, however this has
not been shown to be the case in asthma, and our data
refutes this assertion.
It is interesting that during the acute reversibility testing,
there was a larger response to the bronchodilator given first,
regardless of drug. It is known that there are pre-junctional
b2 receptors on cholinergic nerves that act to attenuate
airway cholinergic tone. Thus, b2 agonists have a dual
mechanism—by direct stimulation of b2 receptors on bron-
chial smooth muscle cells and indirectly by down-regulating
cholinergic tone. If salbutamol is given first, the subsequent
ipratropium has less effect due to the partial blockade of
cholinergic transmission by prior salbutamol. However, if
ipratropium is given first, cholinergic transmission is com-
pletely blocked, thus the subsequent salbutamol dose has
only a single effect, directly on smooth muscle b2 receptors.
Also the blockade of M2 receptors caused by ipratropium
effectively ‘‘brakes’’ the effect of adrenergic agonism.
The results from acute reversibility testing with short
acting b2 agonists and short acting anti-cholinergics did not
predict which patients would have a similar response to
either salmeterol or tiotropium, therefore we do not
recommend withholding either medication due to lack of
response to the short-acting moieties.
One could postulate that, in patients with severe asthma,
the magnitude of the bronchodilator signal from effort
independent tests of pulmonary function may be greater than
those which are effort dependent, as effort dependent
closure of small airways may significantly alter results in
forced expiratory manoeuvres. This may be seen on the
expiratory flow volume loops of our patients, who all had
severe volume dependent airway closure with a mean
FEF2575 of 30% predicted. In the present study, the use of
body plethysmography provided no additional benefits over
conventional effort-dependent forced expiratory manoeuvres
in terms of detecting a signal from additional bronchodilator
therapy. In both treatment limbs within the study there was
improvement in RAW, however this was matched by similar
improvements PEF and, for salmeterol and tiotropium, FEV1
and FVC were also significantly improved. Body plethysmo-
graphy requires expensive equipment, expertise in its use and
is time consuming. If it does not appear to add to simple
measures of pulmonary function, its use in routine clinical
practice is cast into doubt.
ARTICLE IN PRESS
To evaluate the dose of fluticasone in combination with salmeterol and tiotropium 1227Our patient cohort had severe asthma with markedly
impaired airway calibre (FEV1 ¼ 51% predicted, FVC ¼ 65%
predicted, FEF2575 ¼ 30% predicted, PEF ¼ 63% predicted).
There have been few studies examining the effects of long-
acting bronchodilators in this cohort of patients. It is known
that severe asthmatic patients develop irreversible airway
obstruction as a consequence of long-standing active
inflammation.33 The airways of these patients progress to
resemble, microscopically, those of patients with smoking
induced COPD.11 Tiotropium has been shown to be of benefit
in COPD34–41 improving pulmonary function42 and quality-of-
life scores.43 We did not show similar results in terms of
adding tiotropium to salmeterol; however, the study was
powered on pufunction and was not sufficiently powered to
detect improvements in quality of life, as such. Further,
longer-term studies are required in severe asthmatic
patients to assess whether small improvements in lung
function conferred by step-down therapy in conjunction
with salmeterol and tiotropium may translate into subjec-
tive improvements in quality of life and objective reductions
in exacerbations. This in turn would determine whether a
single, triple-combination inhaler would give a therapeutic
advantage for such patients with severe asthma.
Although there was no demonstrable change in quality of
life endpoints during the study, the numbers of subjects
were small, as the study was not powered on these
outcomes. The severe asthmatic population have significant
co-morbidity, and it is possible that improvements in
asthma-related quality of life may be masked by overall
ill health and poor quality of life. A longer, larger study
would be indicated to demonstrate any improvement in
subjective quality of life. During the study, 8 patients
dropped out due to exacerbations of asthma. This is clearly
a major problem in the severe cohort of patients. A longer
term study, powered on exacerbation rate, may elucidate
further benefits of triple therapy for asthma which this study
could not.
In conclusion, the addition of salmeterol and tiotropium
in association with halving the dose of fluticasone propio-
nate in severe asthmatics leads to small improvements in
effort dependent and independent pulmonary function
outcomes, but not quality-of-life scores. There may be a
role for tiotropium in the management of severe asthmatics,
and may facilitate the reduction of inhaled corticosteroid
doses, reducing side effects. The magnitude of improve-
ments in pulmonary function provided by salmeterol and
tiotropium were not predicted by the acute reversibility to
salbutamol and ipratropium.
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